CLOs on the Move

Armetheon

www.armetheon.com

 
Armetheon, Inc. is a privately held San Francisco Bay area-based biopharmaceutical company with late-stage clinical drug candidates in development for cardiovascular diseases. The company was founded in 2011 by experienced biotech entrepreneurs and drug developers. Armetheon’s two late-stage small molecule drug candidates are for use in the areas of oral anti-coagulation and anti-arrhythmia for atrial fibrillation. The company was founded with the idea that drug innovations can happen by building on the success of proven medications. We create solutions that are within the same class of medication and that utilize the same mechanism of action as existing therapies. This development approach has the ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.armetheon.com
  • 3375 Scott Blvd Suite 306
    Santa Clara, CA USA 95054
  • Phone: 650.646.3898

Executives

Name Title Contact Details

Similar Companies

Octec

Octec is a Billerica, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SurgiTel

SurgiTel is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Cardiac Science Corporation

Cardiac Science Corporation develops, manufactures and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AEDs), electrocardiograph systems, stress test systems, Holter

Global Orthodontics

Global Orthodontics is a Fairfax, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elucid

Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid equips physicians with critical information designed to enable precision medicine. Elucid is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts (“Virtual Transcriptomics”). This unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs. The Elucid software is available for commercial use in the U.S. and Europe